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Purpose
The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients
after they have undergone curative resection, and we also wanted to identify the prognostic
factors according to the clinico-pathologic features.
Materials and Methods
Between January 2000 and December 2004, we retrospectively reviewed the medical
records of the patients with histologically confirmed pN3 stage gastric cancer. They
underwent both gastrectomy and lymphadenectomy with a curative aim. We categorized
the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3
combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or
para-aortic LN metastasis. 
Results
Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients
underwent curative resection and they were pathologically staged as N3. Among these 260
patients, 78 patients were classified as the pN3/M1 stage. For all the patients, the median
follow-up period was 19 months (range: 1?108 months) and the median overall survival time
was 16.2 months (95% CI, 14.1?18.3%). The 5-year survival rate of the pN3/M0 group was
significantly higher than that of the pN3/M1 group (12.6% vs. 2.6%, respectively, p?0.0001).
The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI,
1.4?8.3, p=0.008) for the pN3 patients. 
Conclusion
The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly
longer in the pN3/M0 group as compared to that of the pN3/M1 group. An advanced T stage
was a predictor for a poor prognosis for the pN3 patients. Therefore, diverse treatment
strategies for these heterogeneous pN3 gastric cancer patients are needed for improving
their survival.
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I n t r o d u c t i o n
Gastric cancer is the fourth most common cancer worldwide (1).
According to the global estimation-GLOBOCAN 2002, gastric cancer
has the second and fourth highest mortality rate for men and women,
respectively (2). The prognosis of gastric cancer patients is poor with a
5-year survival rate of approximately 20% (1,3). Surgical resection
with a curative aim is the principal treatment for gastric cancer and the
indications for surgical resection have been decided on based on the
stage (4). The fifth edition of the American Joint Committee on Cancer
(AJCC) cancer staging system has been modified with the main
change of nodal staging which was based on the number of metastatic
lymph nodes (5). When applying the fifth AJCC system, some studies
have reported 23% of the patients migrated to another stage, including
the patients who migrated to stage IV (5). Thus, there are variations in
the survival rates even among the patients with the same stage IV
gastric cancer. It is still controversial that these heterogeneous groups
of patients are being treated with the same strategies according to the
grouping as stage IV. 
For the stage IV patients who cannot be cured, several studies have
shown that resection may be beneficial in terms of survival (4). The
benefit of surgery has been reported that the survival of patients with
stage IV gastric cancer was significantly better with resection than with
bypass procedures or laparotomy alone (6). In addition, it has also been
reported that the patients with pN3/M0 gastric cancer showed a higher
survival rate among the stage IV patients with other pathologic
characteristics (7). It has been found that the 5-year survival rate of
pN3M0 gastric cancer was 8.7%, which was slightly better than that of
other stage IV gastric cancers (about 4.1%) (p=0.039) (7). 
We hypothesize that the prognosis may be different among stage IV
patients, and especially between the pN3 stage patients whose tumor
was removed and the other stage IV gastric cancer patients with gross
residual tumors. Therefore, the aim of this study was to determine
whether the pN3 stage gastric cancer patients are a heterogeneous
group with different prognoses among the stage IV patients. We also
determined the prognostic factors of pN3 stage gastric cancer patients
according to the clinico-pathologic features.
M a t e r i a l s  a n d  M e t h o d s
1 Patients
Between January 2000 and December 2004, among 467 patients
with histopathologically diagnosed stage IV adenocarcinoma and who
received surgical treatment at the Yonsei Cancer Center, Yonsei
University Health System, we enrolled 260 patients who underwent
surgery for primary gastric cancer and they were staged at the pN3
stage. The last follow up date was December 31 2008. 
The pathology was confirmed as gastric adenocarcinoma according
to endoscopic biopsy. Preoperative computed tomography was done to
evaluate for possible metastatic disease in the abdominal organs and
lymph nodes. All the enrolled patients had the following curative aim
for their operative procedures: 1) total or subtotal gastrectomy
depending on the location and 2) D2 or D3 lymphadenectomy.
Curative resection was defined as having no remaining grossly visible
tumor tissue and microscopically negative surgical margins on the
sufficient margins around the tumor. A margin of 2 cm for expanding
tumors and a 2?3 cm distal surgical margin for the pylorus were
regarded as sufficient (8). M1 stage was defined in this study as
metastasis with peritoneal seeding or hepatic metastasis or the presence
of para-aortic lymph node metastasis. 
Lymph node dissection followed the guideline of the Japanese
Research Society for Gastric Cancer (JRSGC) (9). D2 lymphadenec-
tomy was performed for all the Group 1 and Group 2 lymph nodes,
and D3 lymphadenectomy was performed for all the Group 1, Group 2
and Group 3 lymph nodes. The retrieved lymph nodes were classified
by the surgeons in the operation rooms and all the lymph nodes were
inspected by light microscopy for metastasis. The pN3 stage was
defined as metastasis in more than 15 regional lymph nodes according
to the sixth edition of the UICC TNM classification.
The clinical and pathological features of the N3 patients were
retrospectively reviewed. We then analyzed survival according to such
factors as age, gender and tumor location, the type of gastrectomy, the
gross features of the tumor, tumor size, tumor differentiation, the depth
of invasion, Lauren classification, lymphatic invasion, vascular
invasion and the number of retrieved and metastatic lymph nodes. 
We subdivided the patients into two groups as the pN3/M0 group
and the pN3/M1 group: 1) the pN3/M0 group was diagnosed as the
pN3 stage only and they had no distant metastasis or para-aortic lymph
node metastasis, 2) the pN3/M1 group was diagnosed as the pN3 stage
with peritoneal metastasis, hepatic metastasis or para-aortic lymph
node metastasis (Table 1).
2 Statistical analysis
The end point of this study was overall survival, and this was
defined as the time from operation to death or to the last follow-up
date. We analyzed the overall survival of the total patients and we
compared survival of the pN3/M0 group with that of the pN3/M1
group. We also investigated the significant prognostic factors for all the
cases of pN3 gastric cancer and for the two groups. We used X2-square
or Fisher’s exact tests, except for the comparisons of age and tumor
size for which we used the Mann-Whitney U test. We calculated the
probability of survival using the Kaplan-Meier method. The
differences between survival curves were calculated by the log-rank
test. The multivariate analysis was done using the Cox proportional
hazard model, and the hazard ratios were calculated. A p-value of
?0.05 was considered statistically significant. 
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Characteristics - no. (%) Number of patients pN3/M0  (n=182) pN3/M1 (n=78) p-value
Age (yr)
Median (range) 59 (16?82) 62 (16?82)                   54.5 (28?75) 0.006
Gender 0.313
Male 175 (67.3) 119 (65.4) 56 (71.8)
Female 85 (32.7) 63 (34.6) 22 (28.2)
Type of gastrectomy 0.010 
Total 166 (63.8) 107 (58.8) 59 (75.6)
Subtotal 94 (36.2) 75 (41.2) 19 (24.4)
Location 0.274?
Upper 37 (14.2) 28 (15.5) 9 (12.0)
Middle 95 (36.5) 61 (33.7) 34 (45.3)
Lower 119 (45.8) 89 (49.2) 30 (40.0)
Diffuse 5 (1.9) 3 (1.7) 2 (2.7)
Unknown 4 (1.5) 1 (0.5) 3 (3.8)
Borrmann type 0.466?
1 4 (1.5) 3 (1.6) 1 (1.3)
2 54 (20.8) 33 (18.1) 21 (26.9)
3 116 (44.6) 84 (46.2) 32 (41.0)
4 85 (32.7) 61 (33.5) 24 (30.8)
Unknown 1 (0.4) 1 (0.5) 0 (0)
Tumor size 0.158
Median (range) 7 (2?28) 7 (2?20) 8 (3?28)
?10 cm 193 (74.2) 137 (75.3) 56 (71.8)
?10 cm 66 (25.4) 45 (24.7) 21 (26.9)
Unknown 1 (0.4) 0 (0) 1 (1.3)
Histological type 0.362?
Poorly differentiated 153 (58.8) 109 (59.9) 44 (56.4)
Well, moderate differentiated 56 (21.5) 34 (18.7) 22 (28.2)
Signet ring cell 38 (14.6) 29 (15.9) 9 (11.5)
Mucinous 13 (5.0) 10 (5.5) 3 (3.8)
Depth of invasion ?0.0001?
T1 0 (0) 0 0 (0)
T2 9 (3.5) 8 (4.4) 1 (1.3)
T3 222 (85.4) 163 (89.6) 59 (75.6)
T4 29 (11.2) 11 (6.0) 18 (23.1)
Lauren classification 0.957?
Intestine 37 (14.2) 26 (14.3) 11 (14.1)
Diffuse 65 (25) 44 (24.2) 21 (26.9)
Mixed 13 (5) 9 (4.9) 3 (5.1)
Unknown 145 (55.8) 103 (56.6) 36 (46.2)
Lymphatic invasion 0.552?
Negative 3 (1.2) 3 (1.6) 0 (0)
Positive 191 (73.5) 126 (69.2) 65 (83.3)
Unknown 66 (25.4) 53 (29.1) 13 (16.7)
Vascular invasion 0.334
Negative 21 (8.1%) 16 (8.8) 5 (6.4)
Positive 163 (62.7) 107 (58.8) 56 (71.8)
Unknown 76 (29.2) 59 (32.4) 17 (21.8)
?Fisher’s exact test.
Table 1. The patients’ characteristics and univariate analysis between the pN3/M0 group (diagnosed with pN3 stage only) and the pN3/M1
group (diagnosed with pN3 stage and M1 stage by peritoneal metastasis, hepatic metastasis and para-aortic lymph node metastasis)
R e s u l t s
1 Characteristics of the patients
Among the 260 gastric cancer patients who underwent gastrectomy
and who were finally confirmed as being pN3 stage, there were 175
(67.3%) males and 85 (32.7%) females. The clinico-pathology features
of the patients are shown in Table 1. The median age of the 260
patients was 59 years (range: 16?82 years). 
The number of patients who underwent curative resection and who
were confirmed as having pN3 stage disease was 182 (70%) and the
number of pN3 with M1 stage patients was 78 (30%). Among them,
only 12 of the patients were pathologically confirmed as having para-
aortic lymph node metastasis (Fig. 1). Thirty-one patients had
peritoneal seeding and 18 patients had hepatic metastasis or other organ
metastasis.
The most common site of gastric cancer was the lower third of the
stomach (45.8%) followed by the middle third of the stomach (36.5%)
and the upper third (14.2%). Twenty five percent of the patients had the
diffuse type tumor according to Lauren classification. The median
tumor size of all the patients was 7 cm (range: 2?28 cm). For the
depth of invasion, no cases of T1 stage existed, while the number of
T2, T3 and T4 stages was 9 (3.5%), 222 (85.4%) and 29 (11.2%),
respectively. Among the clinico-pathologic parameters, there were
significant differences between the pN3/M0 patients and the pN3/M1
patients for age (p=0.006), the type of gastrectomy (p=0.010) and the
depth of invasion (p?0.0001). 
2 Survival analysis of the pN3 stage gastric cancer patients 
With a median follow-up period of 19 months (range: 1?108), the
median overall survival time of all the patients was 16.2 months (95%
CI, 14.1?18.3%). The overall 3-year and 5-year survival rates were
23.1% and 9.6%, respectively. When we compare the survival
between the two groups, the survival rate of the pN3/M0 group was
higher than that of the pN3/M1 group with the 3-year survival rates
being 27.5% vs. 12.8%, respectively, and the 5-year survival rates were
12.6% vs. 2.6%, respectively. The median survival time of the
Cancer Res Treat. 2009;41(2):73-79
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Fig. 1. Diagram of the enrolled patients.
Fig. 2. Overall survival of the pN3 gastric cancer patients according
to the pathology.
Fig. 3. The overall survival curve of the pN3 gastric cancer patients
according to the T stage.
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pN3/M0 group was 19.2 months (95% CI, 14.9?23.4%) and this was
significantly longer as compared with the median survival time of 10.7
months for the pN3/M1 group (95% CI, 8.5?12.8%, p?0.0001) (Fig.
2). For the depth of invasion, an advanced T stage showed a worse
prognosis (p=0.003) and the median survival times for T2 stage, T3
stage and T4 stage were 39.7 months (95% CI, 0.00?95.02%), 16.6
months (95% CI, 14.21?18.99%) and 11.3 months (95% CI, 5.15?
17.45%), respectively (Fig. 3). 
Characteristics Number of patients - no (%) Median survival time (months) 95% CI p-value
Age 0.876
?60 years 137 (52.7) 16.7 13.3?20.1
?60 years 123 (47.3) 16.0 13.2?18.8
Gender 0.256
Male 175 (67.3) 17.0 14.4?19.7
Female 85 (32.7) 14.6 11.2?18.3
Pathology ?0.0001
pN3/M0 182 (70) 19.2 15.0?23.4
pN3/M1 78 (30) 10.7 8.6?12.8
Type of gastrectomy 0.089
Total 166 (63.8) 14.5 12.2?16.9
Subtotal 94 (36.2) 19.5 13.4?25.8
Location 0.155
Upper 37 (14.2) 13.5 8.9?18.0
Middle 95 (36.5) 18.2 15.2?21.1
Lower 119 (45.8) 14.7 0.0?48.9
Diffuse 5 (1.9) 24.2 14.1?18.0
Borrmann type 0.089
1 4 (1.5) 24.2                                                 ?
2 54 (20.8) 19.6 11.9?27.3
3 116 (44.6) 15.6 13.5?17.8
4 85 (32.7) 14.9 11.5?18.4
Tumor size 0.384
?10 cm 193 (74.2) 16.6 14.1?19.1
?10 cm 66 (25.4) 16.2 11.4?21.1
Histological type 0.181 
Poorly differentiated 153 (58.8) 14.6 12.2?17.0
Well, moderate differentiated 56 (21.5) 20.0 8.2?31.8
Signet ring cell 38 (14.6) 12.8 6.0?19.6
Mucinous 13 (5.0) 19.5 17.1?21.9
Depth of invasion 0.003 
T1 0 (0)
T2 9 (3.5) 39.7 0.0?95.0
T3 222 (85.4) 16.6 14.2?19.0
T4 29 (11.2) 11.3 5.1?17.5
Lauren classification 0.713
Intestine 37 (14.2) 14.5 7.3?21.8
Diffuse 65 (25) 13.5 8.7?18.2
Mixed 13 (5) 11.3 4.3?18.3
Lymphatic invasion 0.255
Negative 3 (1.2) 27.6 0.0?64.5
Positive 191 (73.5) 14.5 12.5?16.5
Vascular invasion 0.221
Negative 21 (8.1%) 17.9 10.6?25.1
Positive 163 (62.7) 13.8 11.7?15.9
Table 2. Prognosis of the patients with pN3 stage gastric cancer
3 Prognostic survival factors for the patients with pN3
stage gastric cancer 
The 3-year and 5-year survival rates and the median survival times
according to the clinic-pathologic factors that were analyzed are
summarized in Table 2. The results of the multivariate analysis are
shown in Table 3. 
The factors influencing survival for the patients with pN3 stage
disease were the pN3/M1 group (p?0.0001) and the depth of invasion
(p=0.003). For all the patients, a multivariate analysis that including
four factors (gender, age, the pN3/M1 group and the depth of invasion)
from the univariate analysis showed that an advanced T stage was an
independent prognostic factor for survival (Table 3). The pN3/M1
group had a higher hazard ratio than the pN3/M0 group (hazard ratio:
1.68, 95% CI, 1.26?2.24, p?0.0001). The hazard ratio for the depth
of invasion was 2.21 (95% CI, 0.98?5.03, p=0.058) for the T3 stage
and it was 3.38 (95% CI, 1.38?8.31, p=0.008) for the T4 stage. The
factor influencing survival for the pN3/M0 patients was the Borrmann
type (p=0.039), but the depth of invasion was not a significant factor
for survival (p=0.104, Table not shown). There were no significant
factors for the pN3/M1 patients. A multivariate analysis for the
pN3/M0 patient group included three factors (gender, age and the
Bormann type) from the univariate analysis, but no factors were proven
to be statistically significant. 
D i s c u s s i o n
The prognosis of stage IV gastric cancer has been thought to be poor
and the benefits of surgery are controversial. Some study have reported
longer survival for patients with resected stage IV gastric cancer (10),
and the selected patients with stage IV gastric cancer with acceptable
risk should be considered for surgical resection (11). In addition,
Medina-Franco et al. have reported low surgical mortality and low
morbidity rates when patients with stage IV gastric cancer undergo
surgical resection (6). Radical resection is the standard care for gastric
cancer. Some gastric cancer patients undergo gastrectomy with a
curative aim because they are diagnosed with a tumor at a resectable
stage via imaging studies. Yet some are classified into pathologic stage
IV due to their pN3 stage with or without M1 disease, according to the
AJCC sixth staging system.
The fifth edition of AJCC cancer staging system for gastric cancer is
generally thought to be a good predictor for the prognosis. Compared
to the fourth edition, the N3 stage is based on the number of positive
metastasis lymph nodes, and TanyN3M0 and T4N1M0 are defined as
stage IV in the fifth edition. Stage migration has been detected with a
change of the staging system. Klein et al. reported that some of the
node-positive patients changed to another N stage, including a higher
stage, as compared to the fourth edition (5). In this study, the fifth
edition’s N staging was suggested to be the most significant prognostic
variable. Some studies have also reported the fifth edition of the new
pN classification showed more homogenous survival than the old
classification (12). 
However, some researchers have suggested that stage IV has
heterogeneous prognoses for several groups of patients. Lin et al.
reported that the patients with the N3 stage and who underwent
palliative gastrectomy had much higher 1-year and 2-year survival
rates than the patients who underwent operation without resection (by-
pass or laparotomy exploration only). In this study, the 1 year survival
rate of the patients with N3 lymph node metastasis was 66.7%, which
was comparable to the 64.4% 1 year survival rate of our study (13).
Park el al. suggested sub-classifying stage IV gastric cancer into IVa
(T1-3N3M0, T4N1-2M0) and IVb (T4N3M0, TanyNanyM1) for
better prediction of survival (7). This study showed that the survival of
patients with T1-3N3M0 and T4N1-2M0 stage disease was
significantly longer than that of the patients with stage T4N3M0 and
stage M1 disease. Li et al divided stage IV gastric cancer into four
groups in the same way (14). In addition, An et al. reported on 1056
patients who were divided into three groups: the T4N1M0, T1-3N3M0
and TanyNanyM1 stage groups (15). The patients with the T1-3N3M0
stage showed a better prognosis than the patients with the T4N1-3M0
or the TanyNanyM1 stage. Our analysis also showed a significant
difference of survival between the pN3/M0 group and the pN3/M1
group (19.2 months vs. 10.7 months, respectively, p?0.0001). 
Many studies have reported various prognostic factors for patients
with stage IV gastric cancer. We analyzed the clinic-pathologic
features that were correlated with the survival of pN3 gastric cancer
patients. We found that the depth of invasion was a significant
independent prognostic factor for survival for pN3 gastric cancer
patients. As a result, the T4 stage was a poorer prognostic factor than
the T2 or T3 stage in the patients with pN3 stage gastric cancer. It is
well known that the status of lymph node metastasis is one of the most
Cancer Res Treat. 2009;41(2):73-79
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Table 3. Multivariate analysis of the prognostic factors for the
patients with pN3 stage gastric cancer
Characteristics Hazard ratio 95% CI p-value
Age
?60 1.00 (ref)
?60 1.07 0.8?1.4 0.606
Gender
Male 1.00 (ref)
Female 1.29 0.9?1.7 0.085
Pathology
pN3/M0 1.00 (ref)




T3  2.21 0.9?5.0 0.058
T4  3.38 1.4?8.3 0.008
Jung Ryun Ahn, et al_Prognosis of pN3 Stage Gastric Cancer
significant prognostic factors for gastric cancer patients. However, for
precisely evaluating the lymph node metastasis status, wide dissection
is necessary with a large enough number of dissected lymph nodes. All
of the patients in our study underwent D2 or D3 lymphadenectomy,
and the numbers of dissected lymph nodes were more than 15 (range:
26 to 165). Hence, in the current study, the lymph node status was not
significant for predicting survival, and this suggests the need for
developing different parameters for lymph node metastasis for better
prediction of survival among the pN3 patients.
Some studies have also reported that Borrmann type IV is an
independent prognostic factor (16,17). Our data showed shorter
median survival duration for advanced Borrmann type IV, but the
differences were not statistically significant. In addition, when we
divided the patients based on the tumor size of 10 cm, there was no
survival difference between the groups, and this was different from a
previous report (18). Although there is no internationally accepted
standard of care after cancer surgery, the efficacy of postoperative
chemotherapy cannot be ignored as a prognostic factor for pN3 stage
patients. There have been some studies that showed that postoperative
chemotherapy after D2 surgery was effective (19). In our study, we
couldn’t find a significant survival difference between the patients who
received postoperative chemotherapy and those who didn’t because the
majority of our patients received postoperative chemotherapy. 
We included the sub-classified groups (the pN3/M0 and pN3/M1
groups) as a statistical variable and a significant difference of survival
between the pN3/M0 and pN3/M1 groups was seen. We suggest that
pN3 stage gastric patients have a different prognosis and we should
treat gastric cancer patients with a pN3 stage only (pN3/M0) with
aggressive surgical therapy. But, our patients were somewhat limited to
the pN3 stage after gastrectomy and our study didn’t include palliative
resection for other stage IV patients. There are questions about the
survival advantage of performing resection for stage IV patients, except
for pN3 stage patients. 
C o n c l u s i o n
Although the pN3 stage patients in our study were stage IV, there is
a significant difference in survival between the pN3/M0 group and the
pN3/M1 group. The survival time is significantly longer for the
pN3/M0 group after gastrectomy than for the pN3/M1 group,
suggesting a different tumor burden and degree of tumor extension.
Therefore, diverse treatment strategies are needed for these
heterogeneous pN3 gastric cancer patients to improve their survival.
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